Is IL-6 a key cytokine target for therapy in COVID-19?

The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonist...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Simon A., Hunter, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043092/
https://www.ncbi.nlm.nih.gov/pubmed/33850327
http://dx.doi.org/10.1038/s41577-021-00553-8
_version_ 1783678248138309632
author Jones, Simon A.
Hunter, Christopher A.
author_facet Jones, Simon A.
Hunter, Christopher A.
author_sort Jones, Simon A.
collection PubMed
description The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.
format Online
Article
Text
id pubmed-8043092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80430922021-04-14 Is IL-6 a key cytokine target for therapy in COVID-19? Jones, Simon A. Hunter, Christopher A. Nat Rev Immunol Comment The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here. Nature Publishing Group UK 2021-04-13 2021 /pmc/articles/PMC8043092/ /pubmed/33850327 http://dx.doi.org/10.1038/s41577-021-00553-8 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Jones, Simon A.
Hunter, Christopher A.
Is IL-6 a key cytokine target for therapy in COVID-19?
title Is IL-6 a key cytokine target for therapy in COVID-19?
title_full Is IL-6 a key cytokine target for therapy in COVID-19?
title_fullStr Is IL-6 a key cytokine target for therapy in COVID-19?
title_full_unstemmed Is IL-6 a key cytokine target for therapy in COVID-19?
title_short Is IL-6 a key cytokine target for therapy in COVID-19?
title_sort is il-6 a key cytokine target for therapy in covid-19?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043092/
https://www.ncbi.nlm.nih.gov/pubmed/33850327
http://dx.doi.org/10.1038/s41577-021-00553-8
work_keys_str_mv AT jonessimona isil6akeycytokinetargetfortherapyincovid19
AT hunterchristophera isil6akeycytokinetargetfortherapyincovid19

Ejemplares similares